1. Home
  2. ESGL vs XGN Comparison

ESGL vs XGN Comparison

Compare ESGL & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ESGL
  • XGN
  • Stock Information
  • Founded
  • ESGL 1999
  • XGN 2002
  • Country
  • ESGL Singapore
  • XGN United States
  • Employees
  • ESGL N/A
  • XGN N/A
  • Industry
  • ESGL
  • XGN Medical Specialities
  • Sector
  • ESGL
  • XGN Health Care
  • Exchange
  • ESGL Nasdaq
  • XGN Nasdaq
  • Market Cap
  • ESGL 123.1M
  • XGN 138.3M
  • IPO Year
  • ESGL N/A
  • XGN 2019
  • Fundamental
  • Price
  • ESGL $3.22
  • XGN $6.78
  • Analyst Decision
  • ESGL
  • XGN Strong Buy
  • Analyst Count
  • ESGL 0
  • XGN 2
  • Target Price
  • ESGL N/A
  • XGN $7.50
  • AVG Volume (30 Days)
  • ESGL 83.8K
  • XGN 256.1K
  • Earning Date
  • ESGL 09-03-2025
  • XGN 08-04-2025
  • Dividend Yield
  • ESGL N/A
  • XGN N/A
  • EPS Growth
  • ESGL N/A
  • XGN N/A
  • EPS
  • ESGL N/A
  • XGN N/A
  • Revenue
  • ESGL $6,099,784.00
  • XGN $56,724,000.00
  • Revenue This Year
  • ESGL N/A
  • XGN $18.92
  • Revenue Next Year
  • ESGL N/A
  • XGN $14.78
  • P/E Ratio
  • ESGL N/A
  • XGN N/A
  • Revenue Growth
  • ESGL N/A
  • XGN 1.78
  • 52 Week Low
  • ESGL $0.90
  • XGN $1.78
  • 52 Week High
  • ESGL $3.87
  • XGN $7.95
  • Technical
  • Relative Strength Index (RSI)
  • ESGL 57.33
  • XGN 46.14
  • Support Level
  • ESGL $2.69
  • XGN $6.57
  • Resistance Level
  • ESGL $3.35
  • XGN $7.15
  • Average True Range (ATR)
  • ESGL 0.32
  • XGN 0.33
  • MACD
  • ESGL -0.03
  • XGN -0.05
  • Stochastic Oscillator
  • ESGL 42.37
  • XGN 25.93

About ESGL ESGL Holdings Limited

ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Share on Social Networks: